Actualités Hutchmed (china) Limited - HCM | Actions London Stock Exchange

Hutchmed (China) Limited Appointment of Independent Non-executive Director

Hutchmed (China) Limited 20 November 2024 HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee ...

Hutchmed China receives first milestone payment for Takeda drug sales

Hutchmed (China) Ltd on Thursday said it will receive a USD20 million payment from its partner Takeda Pharmaceutical ...

Hutchmed (China) Limited Total Voting Rights

Hutchmed (China) Limited 31 October 2024 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ – Thursday, October 31, 2024:...

Hutchmed (China) Limited Vesting of awards under the LTIP

Hutchmed (China) Limited 21 October 2024 Vesting of awards under the Long Term Incentive Plan Hong Kong, Shanghai & Florham Park, NJ...

TOP NEWS: AstraZeneca's Tagrisso plus Orpathys shows promising results

Hutchmed China Ltd on Wednesday said that Tagrisso plus Orpathys showed a high clinically meaningful response rate in ...

Hutchmed (China) Limited SAVANNAH: clinically meaningful response rate

Hutchmed (China) Limited 16 October 2024 HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response...

Takeda Pharmaceutical says Fruzaqla cancer drug gets Japan backing

Takeda Pharmaceutical Co Ltd on Tuesday said it landed an approval for its Fruzaqla drug in Japan. The drug has bee ...

Hutchmed (China) Limited Japan Approval for FRUZAQLA

Hutchmed (China) Limited 24 September 2024 HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda - Approval...

Hutchmed "disappointed" as it withdraws fruquintinib application

Hutchmed (China) Ltd announced on Friday that it has voluntarily withdrawn its supplemental new drug application for ...

Hutchmed (China) Limited Total Voting Rights

Hutchmed (China) Limited 30 August 2024 Total Voting Rights Hong Kong, Shanghai, & Florham Park, NJ - Friday, August 30, 2024:...

Hutchmed (China) Limited Update on Fruquintinib for Gastric Cancer in China

Hutchmed (China) Limited 30 August 2024 HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China Hong Kong, Shanghai...

Hutchmed (China) Limited Standard form for notification of major holdings

Hutchmed (China) Limited 22 August 2024 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent...

Hutchmed (China) Limited LTIP and Share Option Scheme

Hutchmed (China) Limited 06 August 2024 Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan Hong...

Hutchmed confident of full year guidance for oncology and immunology

Hutchmed (China) Limited on Wednesday said it remains on track to meet full year guidance for its oncology/immunology ...

Hutchmed (China) Limited 2024 Interim Results and Business Updates

Hutchmed (China) Limited 31 July 2024 HUTCHMED Reports 2024 Interim Results and Provides Business Updates Hong Kong, Shanghai & Florham...

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

	Prix en temps réel	Carnet d'ordres
BATS Europe
Chi-X Europe
Euronext

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Hutchmed (china) Limited (HCM)

Votre Hub pour des idées et discussions en direct en temps réel

HCM Actualités

Hutchmed (China) Limited Appointment of Independent Non-executive Director

Hutchmed China receives first milestone payment for Takeda drug sales

Hutchmed (China) Limited Total Voting Rights

Hutchmed (China) Limited Vesting of awards under the LTIP

TOP NEWS: AstraZeneca's Tagrisso plus Orpathys shows promising results

Hutchmed (China) Limited SAVANNAH: clinically meaningful response rate

Takeda Pharmaceutical says Fruzaqla cancer drug gets Japan backing

Hutchmed (China) Limited Japan Approval for FRUZAQLA

Hutchmed "disappointed" as it withdraws fruquintinib application

Hutchmed (China) Limited Total Voting Rights

Hutchmed (China) Limited Update on Fruquintinib for Gastric Cancer in China

Hutchmed (China) Limited Standard form for notification of major holdings

Hutchmed (China) Limited LTIP and Share Option Scheme

Hutchmed confident of full year guidance for oncology and immunology

Hutchmed (China) Limited 2024 Interim Results and Business Updates

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Hutchmed (china) Limited (HCM) Actualités

Hutchmed (china) Limited (HCM)

Votre Hub pour des idées et discussions en direct en temps réel

HCM Actualités

Hutchmed (China) Limited Appointment of Independent Non-executive Director

Hutchmed China receives first milestone payment for Takeda drug sales

Hutchmed (China) Limited Total Voting Rights

Hutchmed (China) Limited Vesting of awards under the LTIP

TOP NEWS: AstraZeneca's Tagrisso plus Orpathys shows promising results

Hutchmed (China) Limited SAVANNAH: clinically meaningful response rate

Takeda Pharmaceutical says Fruzaqla cancer drug gets Japan backing

Hutchmed (China) Limited Japan Approval for FRUZAQLA

Hutchmed "disappointed" as it withdraws fruquintinib application

Hutchmed (China) Limited Total Voting Rights

Hutchmed (China) Limited Update on Fruquintinib for Gastric Cancer in China

Hutchmed (China) Limited Standard form for notification of major holdings

Hutchmed (China) Limited LTIP and Share Option Scheme

Hutchmed confident of full year guidance for oncology and immunology

Hutchmed (China) Limited 2024 Interim Results and Business Updates

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Vendredi fou

Jusqu'à 65% de réduction sur Intégral

Cours Euronext Niveau 1 et carnet d'ordres